• Publications
  • Influence
A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease.
TLDR
An expert panel to review and develop standard terminologies and definitions related to wasting, cachexia, malnutrition, and inflammation in CKD and AKI recommends the term 'protein-energy wasting' for loss of body protein mass and fuel reserves. Expand
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
TLDR
Reduction of LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of major atherosclerotic events in a wide range of patients with advanced chronic kidney disease. Expand
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
TLDR
In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal events than was placebo when added to standard care. Expand
Review on uremic toxins: classification, concentration, and interindividual variability.
TLDR
Concentrations of retention solutes in uremia vary over a broad range, from nanograms per liter to grams per liter, and a substantial number of molecules are protein bound and/or middle molecules, and many of these exert toxicity and are characterized by a high range of toxic over normal concentration (CU/CN ratio). Expand
Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.
TLDR
It is suggested that a considerable number of hemodialysis patients exhibit an activated acute phase response, which is closely related to high levels of atherogenic vascular risk factors and cardiovascular death. Expand
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
TLDR
Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care. Expand
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
TLDR
A multicenter, randomized, double-blind, prospective study of 1255 subjects with type 2 diabetes mellitus receiving maintenance hemodialysis who were randomly assigned to receive 20 mg of atorvastatin per day or matching placebo found the median level of low-density lipoprotein cholesterol was reduced. Expand
Oxidative stress in end-stage renal disease: an emerging threat to patient outcome.
TLDR
It is important to consider oxidative stress as a potentially important source of patient morbidity and mortality, although this knowledge is not yet immediately applicable in the clinical arena. Expand
Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study
TLDR
AHSG deficiency is associated with inflammation and links vascular calcification to mortality in patients on dialysis and might account for accelerated atherosclerosis in uraemia. Expand
Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM).
TLDR
This consensus statement of current knowledge on the etiology of PEW syndrome in CKD is provided to increase awareness, identify research needs, and provide the basis for future work to understand therapies and consequences of Pew. Expand
...
1
2
3
4
5
...